Trial · NCT04983160
Crossover Clinical Trial, Randomized, Double Blind, Placebo Controlled Trial
NCT04983160, Phase 2, Completed, Maimónides Biomedical Research Institute of Córdoba
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Crossover Clinical Trial, Randomized, Double Blind, Placebo Controlled Trial. Trials, record NCT04983160. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04983160
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Crossover Clinical Trial, Randomized, Double Blind, Placebo Controlled Trial
- NCT number
- NCT04983160
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 22 participants, actual
- Lead sponsor
- Maimónides Biomedical Research Institute of Córdoba
- Conditions
- Chronic Kidney Disease
- Interventions
- Allopurinol, Placebo
- First posted
- 2021-07-30
- Last updated
- 2021-07-30
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Circulating endothelial progenitor cells concentration and microparticles derived from endothelial cells | Data collected after 4 weeks, 8 weeks and 12 weeks. | Effect of inhibiting xanthine oxidase with allopurinol in patients with CKD |
| Secondary | Level of oxidative stress | After patient visit (0 weeks, 4, 8 and 12 weeks) | Evaluated through quantification of oxygen-reactive species |
| Secondary | Level of micro inflammation | After patient visit (0 weeks, 4, 8 and 12 weeks) | Evaluated through quantification of C-reactive protein, proinflammatory cytokines, CD14+ and CD16+ monocytes |
| Secondary | Level of endothelial dysfunction | After patient visit (0 weeks, 4, 8 and 12 weeks) | Endothelium-dependant vasodilation in response to ischemia evaluated through changes in capillar flux using Doppler laser PeriFlux system 5000 |
| Secondary | Blood pressure | Each visit (0 weeks, 4 weeks, 8 weeks and 12 weeks) for 24 hours | |
| Secondary | Glomerular filtration ratio | After patient visit (0 weeks, 4 weeks, 8 weeks and 12 weeks) | Estimated through MDRD-4 y Cockroft-Gault. |
| Secondary | Microalbuminuria / Proteinuria | Daily, using first urine of the day as a sample. | Evaluated through albumin/creatinin ratio and protein/creatinine ratio |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04983160
GET https://conductscience.org/api/trials/v1/NCT04983160/registered